Loading
HKSEHealthcareBiotechnology
Latest quote
HK$0.068
+HK$0.001 · +1.49%
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
Latest quote
HK$0.068
+HK$0.001 · +1.49%
Regular session · HKT · Market data may be delayed.
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
Day range
Current HK$0.068
52-week range
Current HK$0.068
Regular session · HKT · Market data may be delayed.
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
Day range
Current HK$0.068
52-week range
Current HK$0.068
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (HKD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 586.21M HKD | 552.98M HKD | 484.72M HKD | 440.32M HKD | 353.41M HKD |
| Cost of goods sold | 98.65M HKD | 91.91M HKD | 91.9M HKD | 105.43M HKD | 76.4M HKD |
| Gross profit | 487.56M HKD | 461.07M HKD | 392.82M HKD | 334.88M HKD | 277.01M HKD |
| Research and development | 44.14M HKD | 56.66M HKD | 36.4M HKD | 35.78M HKD | 50.22M HKD |
| Selling, general, and administrative | 353.47M HKD | 312.42M HKD | 288.65M HKD | 258.31M HKD | 232.85M HKD |
| Operating expenses | 397.61M HKD | 371.2M HKD | 325.05M HKD | 292.63M HKD | 287.89M HKD |
| Interest income | 3.06M HKD | 3.35M HKD | 1.35M HKD | 1.3M HKD | 471K HKD |
| Interest expense | 1.51M HKD | 1.19M HKD | 783K HKD | 376K HKD | 477K HKD |
| Depreciation and amortization | 11.09M HKD | 21.35M HKD | 16.88M HKD | 17.55M HKD | 20.85M HKD |
| Operating income | 89.96M HKD | 89.87M HKD | 67.77M HKD | 38.05M HKD | −6.79M HKD |
| Net income | 93.33M HKD | 82.77M HKD | 70.88M HKD | 38.51M HKD | −19.59M HKD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.0028
2025 complete year+23.7% since 2007
2026 partial: HK$0.0031
HK$0.0022
2,007
HK$0.0028
2,025
HK$0.0031
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 28, 2026 | HK$0.0031Annual | May 29, 2026 | Jun 12, 2026 |
Dividend | May 28, 2025 | HK$0.0028Annual | May 29, 2025 | Jun 13, 2025 |
Dividend | Aug 22, 2007 | HK$0.006Special | — | — |
Ex-dividend May 28, 2026
HK$0.0031
Annual
Record May 29, 2026 · Payment Jun 12, 2026
Ex-dividend May 28, 2025
HK$0.0028
Annual
Record May 29, 2025 · Payment Jun 13, 2025
Ex-dividend Aug 22, 2007
HK$0.006
Special
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
